To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIM0278 in Chinese Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-23

Study Completion Date

2025-07-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1, randomized, double-blind, placebo-controlled trial of SIM0278 in healthy subjects. The study will be conducted in 2 parts. Part 1 is single ascending dose study. Part 2 is multiple ascending dose study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SIM0811 Injection in Healthy Chinese Adult Subjects

NCT07345364

Health, Subjective

NOT_YET_RECRUITING PHASE1

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection

NCT07241923

Healthy Subjects (HS)

RECRUITING PHASE1

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061

NCT07241910

Healthy Subjects

NOT_YET_RECRUITING PHASE1

A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

NCT02470286

Healthy

COMPLETED PHASE1

A Study of SGB-9768 in Adult Healthy Volunteers

NCT06501573

Healthy Volunteer

ACTIVE_NOT_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will assess the safety, tolerability, and pharmacokinetics（PK） after a single or multiple administration of SIM0278 or placebo via subcutaneous injection in healthy subjects (male or female) where PK, pharmacodynamics (PD) and biomarkers will be assessed. Approximately 68 subjects (up to 84) will be enrolled in the whole study. The ratio of active drug to placebo in each dose level will be 3:1. In part1, approximately 44 subjects (up to 52) will be enrolled for the single dose escalation. Six dose levels are planned in part 1. In part2, approximately 24 (up to 32) subjects will be enrolled for the multiple dose escalation. Three dose levels are planned in part 2.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject must be 18 to 55 years of age (inclusive), at the time of signing the informed consent.
2. Body Mass Index (BMI) ≥ 18 and ≤ 28 kg/m2 and weight at least 45 kg at screening.
3. A condition of general good health, as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, vital signs, laboratory profile, a 12-lead electrocardiogram (ECG) and chest X-ray.
4. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

* Not a woman of childbearing potential (WOCBP) as defined in, OR
* A WOCBP who agrees to follow the contraceptive guidance in from screening through at least 90 days after the last dose of study drug; a WOCBP must have a negative beta-human chorionic gonadotropin (β-hCG) test at screening and baseline prior to administration of investigational product.
5. A male subject must agree to use contraception as detailed in this protocol from screening through at least 90 days after the last dose of study drug. Sperm donation is also restricted during the time-frame that males must practice highly effective method of contraception. This criterion may be waived for male subjects who have had a vasectomy more than (\>) 90 days prior to screening.
6. Must voluntarily sign and date each informed consent approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Exclusion Criteria

1. History of significant sensitivity to any drug or previous severe adverse reaction to subcutaneous medication.
2. Subject has a history of any clinically significant cardiac, respiratory (including asthma, bronchospasm), renal, hepatic, gastrointestinal, psychiatric, neurologic, hematologic or rheumatic disease, or psychiatric disease or disorder, current acute or chronic infections, or other abnormality that may affect safety, or potentially influence the study results, judged by the investigator.
3. Chronic or active infection(s) requiring treatment with intravenous anti-infectives within 4 weeks prior to the dose of study drug, or oral anti-infectives within 2 weeks prior to Day 1, or positive test for novel coronavirus antigen or nucleic acid within 4 weeks prior to first dose
4. Evidence or history of malignancy other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma.
5. History of chronic or active hepatitis, or current positive result, including hepatitis B or hepatitis C infection, as evidenced by a positive test for hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab).
6. History of tuberculosis (TB), or active or latent TB on the basis of positive medical history.
7. History of or positive screening test for human immunodeficiency virus (HIV) infection; any genetic, congenital, or acquired immunodeficiency syndrome, or any chronic recurring infections (including mucocutaneous candidiasis).
8. Systolic blood pressure (BP) ≥ 140 mmHg or ≤ 90 mmHg, or diastolic BP≥ 90 mmHg or ≤50 mm Hg, or HR \> 100 bpm, at Screening or baseline，and abnormal clinically significant should be judged by the investigator
9. Subjects with ANY of the following abnormalities in clinical laboratory tests at screening:

* Neutrophil or lymphocyte counts below the normal range; Eosinophil count above the normal range.
* Estimated glomerular filtration rate (GFR) by Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) calculation ≤90 mL/min/1.73 m2 at screening.
* Aspartate aminotransferase (AST)、Alanine transaminase (ALT) \>1.5 x upper limit of normal (ULN)
* Total bilirubin \>1.2 x ULN
* Other clinically significant abnormalities of laboratory assessments, as judged by the Investigator and/or sponsor Medical Monitor, that could affect the safety of the subject, or the interpretation of the data from the study.
10. 12-lead ECG demonstrating QTcF≥450 msec（male）or QTcF≥470 msec（female） at Screening. Subject who have II or III degree atrioventricular block or other clinically significant electrocardiogram abnormalitieshas, in the opinion of the investigator, are unsuitable subjects in the study.
11. Use of prescription or non-prescription drugs (including recreational drugs and herbal medications) within 14 days or 5 half-lives (whichever is longer) prior to Day 1 and/or within the duration of the study.
12. Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1.
13. Prior administration of any IL-2 based product.
14. Exposure to immune-modulating medications (including topical or systemic use of corticosteroids) within 4 weeks prior to Day 1.
15. Receipt of any investigational product within 3 months or 5 half-lives (whichever is longer) prior to Day 1.
16. Will have live vaccine or attenuated live vaccine shots within the 12 weeks prior to Day 1, or planning to receive these vaccines at any time during study period or within 8 weeks after last dose.
17. Current or history of regular alcohol abuse（14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine）within 6 months prior to day 1. OR Positive screen for alcohol breath test during screening period.
18. Take more than 10 cigarettes/day within the last 3 months prior to day 1, and/or unwilling to stop using any tobacco products during the study duration.
19. History of substance abuse, or a positive urine drug screen within 5 years prior to Screening, or urine drug screening result is positive.
20. Donation or loss of 400 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to Day 1.
21. Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to enroll this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes